hVIVO (LON:HVO) Trading Down 46.3% - Here's Why

Shares of hVIVO plc (LON:HVO - Get Free Report) fell 46.3% on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares were traded during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analysts Set New Price Targets

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The business has a 50 day moving average price of GBX 15.98 and a two-hundred day moving average price of GBX 17.81. The company has a market cap of £73.59 million, a P/E ratio of 4.29 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Transactions at hVIVO

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($705,491.02). Corporate insiders own 14.03% of the company's stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.